UkraineTuberculosis profile
Population  2014 45 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 5.7 (5.6–5.8) 13 (13–13)
Mortality (HIV+TB only) 1.2 (0.82–1.6) 2.7 (1.8–3.7)
Prevalence  (includes HIV+TB) 52 (26–86) 114 (57–192)
Incidence  (includes HIV+TB) 43 (38–48) 94 (83–106)
Incidence (HIV+TB only) 8.1 (7–9.3) 18 (16–21)
         
Case detection, all forms (%) 75 (66–84)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 22 (20–24) 56 (50–61)
MDR-TB cases among notified pulmonary
TB cases
5 200 (4 600–5 700) 7 800 (7 000–8 500)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 14 242   4 566
Pulmonary, clinically diagnosed 9 296   800
Extrapulmonary 2 596   201
       
Total new and relapse 31 701    
Previously treated, excluding relapses 8 601    
Total cases notified 40 302    
Among 31 701 new and relapse cases:
532 (2%) cases aged under 15 years; male:female ratio: 2.5
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 13 833 (97%) 9 707 (69%) 23 540
Laboratory-confirmed RR-/MDR-TB cases     7 735
Patients started on MDR-TB treatment ***     8 201
TB/HIV 2014 Number (%)
TB patients with known HIV status 39 057 (97)
HIV-positive TB patients 7 640 (20)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 3 350 (44)
HIV-positive TB patients on antiretroviral therapy (ART) 4 273 (56)
HIV-positive people screened for TB    
HIV-positive people provided with IPT 16 263  
Treatment success rate and cohort size (%) Cohort
New and relapse cases registered in 2013 (71) 29 726
Previously treated cases, excluding relapse, registered in 2013 (55) 9 149
HIV-positive TB cases, all types, registered in 2013 (44) 7 553
RR-/MDR-TB cases started on second-line treatment in 2012 (34) 5 556
XDR-TB cases started on second-line treatment in 2012    
Laboratories 2014  
Smear (per 100 000 population) 1.5
Culture (per 5 million population) 7.2
Drug susceptibility testing (per 5 million population) 2.7
Sites performing Xpert MTB/RIF 25
Is second-line drug susceptibility testing available? Yes, in and outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 123
% Funded domestically 40%
% Funded internationally 19%
% Unfunded 41%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-08-27 Data: www.who.int/tb/data